Health Economics›Papillary renal cell carcinoma›Metastatic disease first-line

Metastatic disease first-line

Papillary renal cell carcinoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cabozantinib monotherapy Variant #01	—	R 90 983	28d	9.0 mo	—	10	R 909 829 PFS proxy	1
Sunitinib monotherapy Variant #05	—	R 33 433	28d	5.6 mo	—	7	R 234 032 PFS proxy	2
Erlotinib monotherapy Variant #01	—	R 13 907	28d	~9.7 mo	~8.8 mo	~11	~R 152 976 PFS proxy · indirect	30

3 of 3 regimens shown